Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

APLS – Apellis Pharmaceuticals, Inc.

Float Short %

20.55

Margin Of Safety %

-8

Put/Call OI Ratio

0.45

EPS Next Q Diff

-1.16

EPS Last/This Y

1.88

EPS This/Next Y

-1.58

Price

22.29

Target Price

33.95

Analyst Recom

1.91

Performance Q

12.92

Upside

-82.5%

Beta

0.24

Ticker: APLS




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23APLS21.760.430.0921435
2026-01-26APLS21.990.440.3021329
2026-01-27APLS21.820.435.0021512
2026-01-28APLS23.110.440.0421530
2026-01-29APLS23.050.430.0321648
2026-01-30APLS22.410.437.0221686
2026-02-02APLS22.820.460.0122038
2026-02-03APLS23.330.460.0822133
2026-02-04APLS23.170.461.1121923
2026-02-05APLS22.640.460.4021887
2026-02-06APLS23.450.461.1821913
2026-02-09APLS22.840.452.7321952
2026-02-10APLS22.580.450.0421862
2026-02-11APLS22.30.45999.9921865
2026-02-12APLS22.130.450.1321980
2026-02-13APLS21.690.451.3921998
2026-02-17APLS21.560.450.0521997
2026-02-18APLS22.180.451.2821905
2026-02-19APLS22.720.460.0522042
2026-02-20APLS22.280.450.1122036
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23APLS21.75-41.1-225.00.28
2026-01-26APLS21.98-38.2-228.10.28
2026-01-27APLS21.82-34.5-225.60.28
2026-01-28APLS23.09-34.5-234.60.28
2026-01-29APLS23.03-34.5-226.40.28
2026-01-30APLS22.57-34.5-223.80.28
2026-02-02APLS22.83-34.5-228.10.28
2026-02-03APLS23.32-34.5-229.60.28
2026-02-04APLS23.17-34.5- 0.28
2026-02-05APLS22.56-36.4- 0.28
2026-02-06APLS23.47-36.4- 0.28
2026-02-09APLS22.83-36.4- 0.28
2026-02-10APLS22.58-36.4- 0.28
2026-02-11APLS22.30-36.4- 0.28
2026-02-12APLS22.03-36.4- 0.28
2026-02-13APLS21.70-36.4- 0.28
2026-02-17APLS21.56-36.4- 0.28
2026-02-18APLS22.19-36.4- 0.28
2026-02-19APLS22.80-36.4- 0.28
2026-02-20APLS22.29-36.4- 0.28
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23APLS-2.31-1.3815.51
2026-01-26APLS-2.31-1.3915.51
2026-01-27APLS-2.31-1.3915.51
2026-01-28APLS-2.31-1.3917.42
2026-01-29APLS-2.31-1.3917.41
2026-01-30APLS-2.32-1.3917.41
2026-02-02APLS-2.32-1.4517.41
2026-02-03APLS-2.32-1.4517.41
2026-02-04APLS-2.32-1.4517.41
2026-02-05APLS-2.32-1.4517.41
2026-02-06APLS-2.32-1.4517.41
2026-02-09APLS-2.32-2.5717.50
2026-02-10APLS-2.27-2.5717.50
2026-02-11APLS-2.27-2.5720.53
2026-02-12APLS-2.27-2.5720.53
2026-02-13APLS-2.27-2.5720.53
2026-02-17APLS-2.272.1820.53
2026-02-18APLS-2.272.1820.53
2026-02-19APLS-2.272.1820.53
2026-02-20APLS-2.252.1820.55
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.69

Avg. EPS Est. Current Quarter

-0.38

Avg. EPS Est. Next Quarter

-0.47

Insider Transactions

-2.25

Institutional Transactions

2.18

Beta

0.24

Average Sales Estimate Current Quarter

200

Average Sales Estimate Next Quarter

193

Fair Value

20.43

Quality Score

78

Growth Score

40

Sentiment Score

94

Actual DrawDown %

76.5

Max Drawdown 5-Year %

-82.5

Target Price

33.95

P/E

75.04

Forward P/E

PEG

P/S

2.77

P/B

7.03

P/Free Cash Flow

35.85

EPS

0.3

Average EPS Est. Cur. Y​

0.28

EPS Next Y. (Est.)

-1.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

4.43

Relative Volume

0.54

Return on Equity vs Sector %

-17.8

Return on Equity vs Industry %

-0.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Apellis Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 705
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
stock quote shares APLS – Apellis Pharmaceuticals, Inc. Stock Price stock today
news today APLS – Apellis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch APLS – Apellis Pharmaceuticals, Inc. yahoo finance google finance
stock history APLS – Apellis Pharmaceuticals, Inc. invest stock market
stock prices APLS premarket after hours
ticker APLS fair value insiders trading